| RS2503122941 |
TTLL5
|
Health Risk |
Pathogenic |
— |
| RS2503123019 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
SPTB-related disorder, SPTB-related disorder |
| RS2503123056 |
FANCM
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2503126790 |
NALCN
|
Health Risk |
Likely pathogenic |
— |
| RS2503126833 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503126847 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503126886 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503126931 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2503126943 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503127787 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503128128 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503128717 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503129066 |
NEMF
|
Health Risk |
Pathogenic |
— |
| RS2503129257 |
SPTB
|
Health Risk |
Pathogenic |
SPTB-related disorder, SPTB-related disorder |
| RS2503130201 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503130437 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503130656 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503131021 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503131597 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503132072 |
MLH3
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, hereditary nonpolyposis |
| RS2503132095 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503132758 |
HIF1A
|
Health Risk |
Likely pathogenic |
Enchondromatosis, Enchondromatosis |
| RS2503132897 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503133074 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503133337 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503133456 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503133461 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503134087 |
TTLL5
|
Health Risk |
Likely pathogenic |
— |
| RS2503134264 |
TTLL5
|
Health Risk |
Pathogenic |
— |
| RS2503144489 |
DDHD1
|
Health Risk |
Pathogenic |
Hereditary spastic paraplegia 28, Hereditary spastic paraplegia 28 |
| RS2503149736 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503149952 |
HIF1A
|
Health Risk |
Likely pathogenic |
Maffucci syndrome, Maffucci syndrome |
| RS2503150240 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503150817 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503151300 |
VIPAS39
|
Health Risk |
Likely pathogenic |
Arthrogryposis, renal dysfunction |
| RS2503151361 |
NEMF
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2503151406 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503151447 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503151450 |
POMT2
|
Health Risk |
Conflicting classifications of pathogenicity |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503152623 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503155082 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503155393 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503155551 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503155683 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503155838 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503156034 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503156139 |
HIF1A
|
Health Risk |
Likely pathogenic |
Enchondromatosis, Enchondromatosis |
| RS2503156182 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503156423 |
TSHR
|
Health Risk |
Pathogenic |
— |
| RS2503156501 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503156505 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503156735 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503156798 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503157018 |
ACTN1
|
Health Risk |
Likely pathogenic |
— |
| RS2503157059 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2503157076 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Elliptocytosis 3 |
| RS2503157131 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503157868 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503158289 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503158326 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503158386 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503158726 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503159407 |
SPTB
|
Health Risk |
Pathogenic |
See cases, See cases |
| RS2503159452 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503160116 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis, Hereditary spherocytosis |
| RS2503160278 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503160291 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503160354 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503160732 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503160747 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503160993 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503161325 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503162227 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503162325 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503162337 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503162476 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503162520 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2503162597 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503162667 |
FANCM
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2503163014 |
FANCM
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2503163092 |
SPTB
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2503163168 |
SPTB
|
Health Risk |
Pathogenic |
SPTB-related disorder, SPTB-related disorder |
| RS2503163247 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503163480 |
SPTB
|
Health Risk |
Pathogenic |
— |
| RS2503165018 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503166655 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503167151 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503167593 |
SPTB
|
Health Risk |
Pathogenic |
SPTB-related disorder, SPTB-related disorder |
| RS2503167736 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503168303 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503170895 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503171373 |
POMT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503171526 |
POMT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 |
| RS2503172640 |
FANCM
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2503172927 |
FANCM
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2503173030 |
SPTB
|
Health Risk |
Likely pathogenic |
— |
| RS2503173041 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503173064 |
SPTB
|
Health Risk |
Pathogenic |
Anemia, Anemia |
| RS2503173177 |
SPTB
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |
| RS2503173416 |
SPTB
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 2, Hereditary spherocytosis type 2 |